FundLens
72
Pharma & HealthcareBuy

Kotak Healthcare

Kotak · Direct–Growth · rank #4 of 19 by Smart Score

Data updated

Trailing returns

vs Nifty 500 (index-fund proxy)
1 Year
33.1%
+32.3% vs index
3 Years
—
5 Years
—
Since launch
23.7%

Year-by-year performance

last entry = YTD
2024
+41.9%
2025
-5.8%
2026
+36.3%

Why this score

Kotak Healthcare scores 72/100 — #4 of 19 Pharma & Healthcare fund (Buy). It stands out for sharpe ratio and alpha — beating 84% of peers on sharpe ratio. It has no major weak spot vs the category.

Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.

Sharpe ratio1.17 · 84th percentile in category
Alpha14.79 · 97th percentile in category
1Y return33.09% · 97th percentile in category
Sortino ratio1.67 · 70th percentile in category
Volatility14.64 · 59th percentile in category
Expense ratio1.03% · 58th percentile in category

Top holdings

top 5 = 37.6% of portfolio
1.Sun Pharmaceutical Industries Ltd13.42%
2.Divi's Laboratories Ltd10.23%
3.Ami Organics Ltd4.88%
4.Molbio Diagnostics Ltd.4.74%
5.Torrent Pharmaceuticals Ltd4.29%

34 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.

Other Pharma & Healthcare funds